NO20061837L - Bicykliske iminosyrederivater anvendt som inhibitorer av matriksmetalloproteinaser - Google Patents

Bicykliske iminosyrederivater anvendt som inhibitorer av matriksmetalloproteinaser

Info

Publication number
NO20061837L
NO20061837L NO20061837A NO20061837A NO20061837L NO 20061837 L NO20061837 L NO 20061837L NO 20061837 A NO20061837 A NO 20061837A NO 20061837 A NO20061837 A NO 20061837A NO 20061837 L NO20061837 L NO 20061837L
Authority
NO
Norway
Prior art keywords
disease
matrix metalloproteinases
inhibitors
acid derivatives
wound healing
Prior art date
Application number
NO20061837A
Other languages
English (en)
Norwegian (no)
Inventor
Hans Matter
Armin Hofmeister
Manfred Schudok
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20061837L publication Critical patent/NO20061837L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20061837A 2003-09-27 2006-04-26 Bicykliske iminosyrederivater anvendt som inhibitorer av matriksmetalloproteinaser NO20061837L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10344936A DE10344936A1 (de) 2003-09-27 2003-09-27 Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
PCT/EP2004/010248 WO2005030728A1 (fr) 2003-09-27 2004-09-14 Derives d'iminoacide bicycliques servant d'inhibiteurs des metalloproteinases matricielles

Publications (1)

Publication Number Publication Date
NO20061837L true NO20061837L (no) 2006-06-01

Family

ID=34353126

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061837A NO20061837L (no) 2003-09-27 2006-04-26 Bicykliske iminosyrederivater anvendt som inhibitorer av matriksmetalloproteinaser

Country Status (24)

Country Link
EP (1) EP1670766B1 (fr)
JP (1) JP4861179B2 (fr)
KR (1) KR20060086367A (fr)
CN (1) CN1856478B (fr)
AR (1) AR046165A1 (fr)
AT (1) ATE550327T1 (fr)
AU (1) AU2004275937A1 (fr)
BR (1) BRPI0414594A (fr)
CA (1) CA2539731A1 (fr)
DE (1) DE10344936A1 (fr)
IL (1) IL174040A0 (fr)
MA (1) MA28075A1 (fr)
ME (1) MEP33008A (fr)
MX (1) MXPA06002927A (fr)
MY (1) MY139830A (fr)
NO (1) NO20061837L (fr)
NZ (1) NZ546158A (fr)
PE (1) PE20050432A1 (fr)
RS (1) RS20060194A (fr)
RU (1) RU2335494C2 (fr)
TW (1) TW200520755A (fr)
UY (1) UY28539A1 (fr)
WO (1) WO2005030728A1 (fr)
ZA (1) ZA200601501B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004031850A1 (de) * 2004-06-30 2006-01-26 Sanofi-Aventis Deutschland Gmbh Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
DE102005002500A1 (de) 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US8790714B2 (en) 2007-08-03 2014-07-29 Nucitec, S.A. De C.V. Compositions and methods for treatment and prevention of osteoarthritis
WO2025224168A1 (fr) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Dérivés d'arylsulfone et de sulfanone utilisés en tant que modulateurs du récepteur de l'orexine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201303B (fr) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
US6207672B1 (en) * 1995-11-13 2001-03-27 Aventis Pharma Deutschland Gmbh Cyclic and heterocyclic N-substituted α-iminohydroxamic and carboxyclic acids
KR100339296B1 (ko) * 1996-08-28 2002-06-03 데이비드 엠 모이어 헤테로고리성 메탈로프로테아제 억제제
PL334846A1 (en) * 1997-01-23 2000-03-27 Hoffmann La Roche Sulphamidic inhibitors of metaloproteases
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
DE10300015A1 (de) * 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln

Also Published As

Publication number Publication date
MY139830A (en) 2009-10-30
TW200520755A (en) 2005-07-01
AR046165A1 (es) 2005-11-30
UY28539A1 (es) 2005-04-29
EP1670766B1 (fr) 2012-03-21
RU2006114352A (ru) 2006-08-27
KR20060086367A (ko) 2006-07-31
NZ546158A (en) 2008-11-28
BRPI0414594A (pt) 2006-11-07
RU2335494C2 (ru) 2008-10-10
WO2005030728A1 (fr) 2005-04-07
CA2539731A1 (fr) 2005-04-07
JP4861179B2 (ja) 2012-01-25
DE10344936A1 (de) 2005-04-21
RS20060194A (sr) 2008-08-07
ZA200601501B (en) 2007-04-25
PE20050432A1 (es) 2005-07-21
JP2007506690A (ja) 2007-03-22
EP1670766A1 (fr) 2006-06-21
ATE550327T1 (de) 2012-04-15
MEP33008A (en) 2010-10-10
IL174040A0 (en) 2006-08-01
MXPA06002927A (es) 2006-06-14
CN1856478A (zh) 2006-11-01
AU2004275937A1 (en) 2005-04-07
CN1856478B (zh) 2010-05-26
MA28075A1 (fr) 2006-08-01

Similar Documents

Publication Publication Date Title
GB0220187D0 (en) Organic compounds
GB0121033D0 (en) Organic compounds
PT1689387E (pt) Inibidores bicíclicos de mek e seus métodos de síntese
ATE331718T1 (de) Spirosubstituierte pyrrolopyrimidine
WO2005090333A8 (fr) 3-'4-heterocyclyl -1,2,3,-triazol-1-yl-n-aryl-benzamides en tant qu'inhibiteurs de la production de cytokines pour le traitement de maladies inflammatoires
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
NO20044038L (no) Glutaminylbaserte DRIV-inhibitorer
WO2006123113A3 (fr) Composes chimiques
WO2007079199A3 (fr) Inhibiteurs de métalloprotéases à base de bisamides substitués
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
WO2006044497A3 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
WO2007011833A3 (fr) Inhibiteurs de spiropiperidine beta-secretase pour le traitement de la maladie d'alzheimer
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
MXPA04001930A (es) Inhibidores de proteasa de cisteina con estructura de 2-ciano-4amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflaciones y otras enfermedades.
WO1997018207A3 (fr) Nouveaux composes macrocycliques tenant lieu d'inhibiteurs de la metalloprotease
NO20071594L (no) Pyrimidinsulfonamidderivater som kjemokinreseptormodulatorer
CL2004000848A1 (es) Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
WO2003065987A3 (fr) Inhibiteurs de granzyme b
ITMI20031311A1 (it) Formulazioni per il trattamento di disturbi artrosici.
WO2003028721A3 (fr) Composes de benzimidazole substitue et utilisation de ceux-ci pour le traitement du cancer
NO20061837L (no) Bicykliske iminosyrederivater anvendt som inhibitorer av matriksmetalloproteinaser
AU7385398A (en) Novel macrocyclic compounds as metalloprotease inhibitors
NO20064982L (no) 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
WO2005073236A3 (fr) Derives de thieno-iminoacide en tant qu'inhibiteurs de metalloproteinases matricielles

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application